Caplin Point Laboratories Limited Stock Price Today (NSE: CAPLIPOINT)
Fundamental Score
Caplin Point Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Caplin Point Laboratories Limited share price today is ₹2583.00, up +0.48% on NSE/BSE as of 16 September 2026. Caplin Point Laboratories Limited (CAPLIPOINT) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹19.63K (Cr). The 52-week high for CAPLIPOINT share price is ₹2877.30 and the 52-week low is ₹1500.30. At a P/E ratio of 29.51x, CAPLIPOINT is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.92% and a debt-to-equity ratio of 0.00.
Caplin Point Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Caplin Point Laboratories Limited share price chart: 5.58% return over the past month. 52-week high ₹2877.30, 52-week low ₹1500.30.
Caplin Point Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2581.00 | ₹2606.70 | ₹2490.50 | ₹2583.00 | 2.12L (Cr) | |
| ₹2750.20 | ₹2760.00 | ₹2555.00 | ₹2570.60 | 2.17L (Cr) | |
| ₹2790.10 | ₹2790.10 | ₹2716.00 | ₹2754.90 | 1.03L (Cr) | |
| ₹2716.00 | ₹2839.50 | ₹2714.00 | ₹2795.40 | 2.46L (Cr) | |
| ₹2789.90 | ₹2798.90 | ₹2707.70 | ₹2723.10 | 1.17L (Cr) | |
| ₹2830.00 | ₹2850.40 | ₹2747.10 | ₹2770.10 | 1.28L (Cr) | |
| ₹2797.10 | ₹2836.00 | ₹2778.00 | ₹2814.00 | 1.11L (Cr) | |
| ₹2845.00 | ₹2845.00 | ₹2759.60 | ₹2810.80 | 2.09L (Cr) | |
| ₹2712.00 | ₹2877.30 | ₹2663.10 | ₹2845.00 | 8.41L (Cr) | |
| ₹2710.00 | ₹2735.80 | ₹2650.00 | ₹2720.50 | 3.74L (Cr) |
Caplin Point Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2514.00 | ₹2877.30 | ₹2490.50 | ₹2583.00 | +2.74% | |
| ₹2516.80 | ₹2672.10 | ₹2382.50 | ₹2517.40 | +0.02% | |
| ₹2652.00 | ₹2699.00 | ₹2435.40 | ₹2516.80 | -5.10% | |
| ₹2024.50 | ₹2675.00 | ₹1950.00 | ₹2626.00 | +29.71% | |
| ₹1710.50 | ₹2099.00 | ₹1710.50 | ₹2024.50 | +18.36% | |
| ₹1565.00 | ₹1799.80 | ₹1508.00 | ₹1709.00 | +9.20% | |
| ₹1680.00 | ₹1710.00 | ₹1500.30 | ₹1504.80 | -10.43% | |
| ₹1790.10 | ₹1939.00 | ₹1681.10 | ₹1700.10 | -5.03% | |
| ₹1840.10 | ₹1871.00 | ₹1672.00 | ₹1773.90 | -3.60% | |
| ₹1911.00 | ₹1992.10 | ₹1747.00 | ₹1838.10 | -3.81% | |
| ₹2032.80 | ₹2074.00 | ₹1879.20 | ₹1910.80 | -6.00% | |
| ₹1973.80 | ₹2086.90 | ₹1960.10 | ₹2032.80 | +2.99% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Caplin Point Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Caplin Point Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CAPLIPOINT across key market metrics for learning purposes.
Positive Indicators
13 factors identified
Strong Return on Equity (19.92%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.50%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (34.61%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (19.63%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (21.37% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (21.49% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (923.75x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 6.97)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1011.97 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
High Price-to-Book Ratio (6.89x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Institutional Interest (FII+DII: 8.29%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Caplin Point Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Caplin Point Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Caplin Point Laboratories LimitedCaplin Point La...Selected✓ CAPLIPOINT • 524742 | 77/100 | ₹2583.00₹2583 | ₹19630.80₹19630.80 | 29.51Average 29.5 Average | 19.92%Good 19.92% Good | 24.50%Excellent 24.50% Excellent | 0.00Excellent 0.0 Excellent | 21.49%Excellent 21.49% Excellent | 15.56%Excellent 15.56% Excellent | 0.23% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Caplin Point Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for CAPLIPOINT — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹70.25 | ₹1838.10 | 26.2x |
| FY 2024 | ₹59.90 | ₹2500.65 | 41.7x |
| FY 2023 | ₹49.18 | ₹1356.15 | 27.6x |
| FY 2022 | ₹39.26 | ₹713.30 | 18.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Caplin Point Laboratories Limited Dividend History
Annual cash dividends paid by CAPLIPOINT — dividend yield 0.23%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹37.99 Cr |
| FY 2024 | ₹34.17 Cr |
| FY 2023 | ₹30.32 Cr |
| FY 2022 | ₹22.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Caplin Point Laboratories Limited Quarterly Performance
Latest quarterly metrics for CAPLIPOINT — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.63%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
15.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.56%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.49%
Compounded annual net profit growth over 5 years
Caplin Point Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CAPLIPOINT — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Caplin Point Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Caplin Point Laboratories Limited (CAPLIPOINT) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Caplin Point Laboratories Limited
About CAPLIPOINT (Caplin Point Laboratories Limited)
Caplin Point Laboratories Ltd is a dynamic pharmaceutical company carving a niche in the global healthcare landscape. Focusing on specialized injectable products and a broad range ...of therapeutic segments, Caplin Point distinguishes itself through its commitment to innovation and affordability. Their state-of-the-art manufacturing facilities, equipped with cutting-edge technology, adhere to stringent international regulatory standards, ensuring the highest quality in every product they deliver. With a strategic emphasis on emerging markets, Caplin Point actively seeks to address unmet medical needs by providing accessible and effective pharmaceutical solutions to patients worldwide. Their dedication to research and development fuels a continuous pipeline of novel formulations, strengthening their position as a significant player in the pharmaceutical industry. Driven by a patient-centric approach, Caplin Point Laboratories manufactures a diverse portfolio encompassing various dosage forms, including sterile injectables, ophthalmics, and oral solids. This comprehensive range enables them to cater to a wide spectrum of medical conditions and patient requirements. Their expertise lies in developing and manufacturing complex generics and niche formulations, offering cost-effective alternatives without compromising on efficacy or safety. The company's vertically integrated operations, from API sourcing to finished product distribution, provide them with greater control over the supply chain, ensuring timely delivery and consistent product quality. This strategic advantage allows Caplin Point to effectively navigate the complexities of the global pharmaceutical market and maintain a competitive edge. Caplin Point Laboratories is deeply rooted in a culture of ethical business practices and sustainable growth. They consistently invest in enhancing their manufacturing capabilities, expanding their product portfolio, and strengthening their global distribution network. By forging strategic partnerships and collaborations, they aim to expand their reach and impact on global healthcare. The company's commitment to social responsibility extends beyond providing affordable medicines, actively engaging in community development initiatives and environmental stewardship. Caplin Point envisions a future where quality healthcare is accessible to all, and they are dedicated to playing a pivotal role in realizing that vision through their innovative pharmaceutical solutions and unwavering commitment to excellence.
Company Details
Key Leadership
CAPLIPOINT Share Price: Frequently Asked Questions
What is the current share price of Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited (CAPLIPOINT) trades at ₹2583.00 on NSE and BSE. Market cap ₹19.63K (Cr). Educational data only.
What is the P/E ratio of Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited has a P/E of 29.51x vs industry average 34.89x.
What is the Bull Run score for Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited has a Bull Run score of 77/100 based on 25+ financial parameters.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited has a dividend yield of 0.23%. Past dividends don't guarantee future payments.
What is the ROE of Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited has ROE of 19.92%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Caplin Point Laboratories Limited?
Caplin Point Laboratories Limited has debt-to-equity of 0.00.
Is Caplin Point Laboratories Limited a good investment?
Bull Run gives Caplin Point Laboratories Limited a score of 77/100. This is not investment advice — consult a SEBI-registered advisor.